Clinical trials: Leptomeningeal Disease, active
HER2-positive Breast Cancer, Leptomeningeal Metastasis
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
The purpose of this study is to find out if radiation therapy followed by intrathecal trastuzumab and pertuzumab is safe and will result in improved survival in HER2 positive breast cancer which has metastasized to the…
- Conditions
- HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
- Trial name
- NCT04588545
- Testing
- Radiation Therapy, Pertuzumab, Trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leptomeningeal Metastasis
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Leptomeningeal metastasis, characterized by tumor cells infiltrating and proliferating in the subarachnoid space, represents a distinct pattern of central nervous system involvement and is a fatal complication of malignant…
- Trial name
- NCT06762080
- Testing
- Cadonilimab (AK104), Pemetrexed (Alimta)
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Guangzhou Medical University
Breast Cancer, Brain Metastases
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
This is a multi-center, open-label, two-cohort study. The purpose of this study is to evaluate the safety, tolerability and efficacy of SHR-A1811 in the treatment of HER2-positive breast cancer with brain and leptomeningeal…
- Conditions
- Breast Cancer, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT07177950
- Testing
- SHR-A1811, radiotherapy
- Volunteers
- 51 people
- Sponsor
- Peking University Cancer Hospital & Institute
Breast Cancer, Leptomeningeal Disease
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), in combination with trastuzumab or nivolumab to confirm the highest dose of the study treatment that can be given…
- Trial name
- NCT07694986
- Testing
- cDC1 Vaccine, Trastuzumab, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leptomeningeal Metastasis From Lung Cancer
ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase
Brief Summary (English) The goal of this clinical trial is to learn if a risk-adaptive consolidation therapy, guided by cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) clearance kinetics after induction intrathecal…
- Trial name
- NCT07751536
- Testing
- proton craniospinal irradiation, Intrathecal pemetrexed
- Where
- 3 sites in China
- Volunteers
- 84 people
- Sponsor
- Shuanghu Yuan
Lung Cancer (NSCLC), Leptomeningeal Metastasis
AI-Based Ultrasound Prediction Model for Intracranial Pressure and Prognosis in Lung Cancer Patients With Leptomeningeal Metastasis: A Dual-Center Study
This study focuses on developing an innovative, artificial intelligence-based model using optic nerve sheath ultrasound videos to predict intracranial pressure in lung cancer patients with leptomeningeal metastasis.
- Conditions
- Lung Cancer (NSCLC), Leptomeningeal Metastasis, Intracranial Pressure
- Trial name
- NCT07005791
- Where
- 2 sites in China
- Volunteers
- 142 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV
Intrathecal Double Checkpoint Inhibition
The objective of the present study is to determine the feasibility and to explore anti-tumor activity of intrathecal double immune checkpoint inhibition for patients with newly diagnosed leptomeningeal metastases from non-small…
- Conditions
- Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV, Melanoma Stage IV
- Trial name
- IT-IO (NCT05598853)
- Testing
- intrathecal nivolumab and intrathecal ipilimumab
- Where
- 3 sites in Switzerland
- Volunteers
- 26 people
- Sponsor
- University of Zurich
Non-Small Cell Lung Cancer
Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
This is a prospective interventional study clinical study to investigate the efficacy and resistance mechanisms of intrathecal pemetrexed in patients with driver gene mutations advanced NSCLC with leptomeningeal metastases.
- Trial name
- EPIC (NCT06440954)
- Testing
- Intrathecal pemetrexed
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Hunan Province Tumor Hospital
NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
A Prospective Study of Zorifertinib Combined with Intra-Ommaya Reservoir Cerebrospinal Fluid Chemotherapy for Leptomeningeal Progression in NSCLC Patients After Third-Generation EGFR-TKI Therapy
- Conditions
- NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis, EGFR-TKI Sensitizing Mutation, Zorifertinib
- Trial name
- NCT07551414
- Testing
- Zorifertinib Plus Intra-Ommaya CSF Chemotherapy
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Brain Cancer, Glioblastoma
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
- Conditions
- Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis
- Trial name
- NCT06058988
- Testing
- Trastuzumab deruxtecan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leptomeningeal Metastases
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
The researchers are doing this study to find out whether deferoxamine (DFO) given intrathecally (directly into the CSF) is a safe treatment for people with leptomeningeal metastasis from solid tumor cancer.
- Trial name
- NCT05184816
- Testing
- Deferoxamine (DFO)
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer, EGFR Mutation
High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
Primary Objective: To evaluate the efficacy of high-dose firmonertinib combined with bevacizumab and intrathecal pemetrexed in EGFR Ex19del/L858R-mutated non-small cell lung cancer (NSCLC) with leptomeningeal metastasis (LM), as…
- Conditions
- Non Small Cell Lung Cancer, EGFR Mutation, Leptomeningeal Metastases, Targeted Therapy
- Trial name
- FLAME-1 (NCT06971406)
- Testing
- Combination therapy prospective cohort
- Volunteers
- 100 people
- Sponsor
- Qiming Wang
Leptomeningeal Metastasis
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors.
- Trial name
- NCT06462222
- Testing
- Toripalimab, pemetrexed
- Where
- 5 sites in China
- Volunteers
- 45 people
- Sponsor
- Guangzhou Medical University
Leptomeningeal Disease
Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease
To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.
- Trial name
- NCT07415018
- Testing
- MRI Scan, VUEWAY, Gadavist
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
HER2-negative Breast Cancer, Leptomeningeal Metastasis
Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
This is a prospective, multicenter, randomized controlled, open-label investigator-initiated clinical study to evaluate the clinical efficacy and quality of life of intrathecal chemotherapy through Ommaya reservoir in combination…
- Trial name
- NCT06230055
- Testing
- Ommaya reservoir, Systematic chemotherapy, Intrathecal chemotherapy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Leptomeningeal Metastases
Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases
With the rapid development of targeted drugs, the treatment of patients with leptomeningeal metastasis has become a very difficult problem in clinical work.
- Trial name
- NCT06861218
- Testing
- pemetrexed, vometinib
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Zhejiang Cancer Hospital
Leptomeningeal Metastasis
Wearable-Triggered Digital Safety Net for Real-Time Monitoring & Intervention in Leptomeningeal Metastasis
This research study is for participants diagnosed with leptomeningeal metastasis disease (LMM), a condition where cancer has spread to the fluid and membranes surround the brain and spinal cord.
- Trial name
- NCT07704034
- Testing
- Calibration Phase, Stepped Wedge Intervention Phase
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Case Comprehensive Cancer Center
Lung Adenocarcinoma EGFR-mutated, Leptomeningeal Metastasis From Lung Cancer
SERS-Based Diagnosis of Leptomeningeal Metastasis in EGFR-Mutant NSCLC
This prospective, multicenter study aims to address the low sensitivity of cerebrospinal fluid (CSF) cytology (60-70%) in diagnosing leptomeningeal metastasis (LM) in patients with EGFR-mutant lung cancer.
- Trial name
- SERS (NCT07912723)
- Testing
- Surface-Enhanced Raman Spectroscopy (SERS) Detection
- Where
- China
- Volunteers
- 74 people
- Sponsor
- limeifang
Leptomeningeal Metastasis of Breast Cancer
Study in Patients With Breast Cancer Leptomeningeal Metastasis
Traditional clinical trials in patients with breast cancer leptomeningeal disease (LMD) are challenging as patients often have a rapidly progressive course and prognosis is poor, making meeting standard eligibility difficult.
- Trial name
- BioLept (NCT06638294)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non Small Cell Lung Cancer
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
A Single-Arm Clinical Study of Furmonertinib (160mg) Combined with Intrathecal Chemotherapy (ITC) and Stereotactic Radiotherapy (SRT) as First-Line Treatment in EGFR Classic Mutation-Positive NSCLC Patients with Brain Parenchymal…
- Trial name
- NCT07304739
- Testing
- Furmonertinib, Intrathecal chemotherapy, Stereotactic radiotherapy
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital